REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
Rhea-AI Summary
REGENXBIO (Nasdaq:RGNX) reported Q1 2026 results and key clinical milestones. Positive topline Phase III AFFINITY DUCHENNE® data for RGX-202 met its primary endpoint with high statistical significance, supporting a potential accelerated approval in 2027.
Q1 2026 revenue was $6.4M versus $89.0M a year ago, with a net loss of $90.1M. Cash and securities totaled $150.5M, expected to fund operations into early 2027. A $100M milestone from AbbVie is expected upon first patient dosing in the NAAVIGATE DR study in Q2 2026.
Positive
- RGX-202 Phase III primary endpoint met; 93% above 10% microdystrophin expression (p<0.0001)
- RGX-202 favorable interim safety profile and functional improvement correlation (NSAA, n=9)
- Planned completion of dosing in 60 RGX-202 pivotal and confirmatory patients by mid-2026
- $100M AbbVie milestone expected upon first patient dosed in NAAVIGATE DR study in Q2 2026
- FDA lifted partial clinical hold on RGX-121 for Hunter syndrome program
- Cash, cash equivalents and securities of $150.5M expected to fund operations into early 2027
- Ongoing royalty entitlement on certain ITVISMA net sales with patents extending until 2037
Negative
- Q1 2026 revenue fell to $6.4M from $89.0M in Q1 2025
- $12.2M decline in ZOLGENSMA royalty revenue due to U.S. patent expirations in January 2026
- Net result swung to $90.1M loss versus $6.1M income in prior-year quarter
- R&D expenses increased to $57.3M from $53.1M, driven by RGX-202 trials and personnel
- General and administrative expenses rose to $21.3M from $20.3M year over year
- Q1 2026 cash balance decreased to $150.5M from $240.9M at December 31, 2025
- Included non-recurring $10M cash payment under settlement agreement with GlaxoSmithKline
News Market Reaction – RGNX
In the May 14 session, RGNX declined 37.80%, reflecting a significant negative market reaction. Argus tracked a trough of -35.6% from its starting point during tracking. Our momentum scanner triggered 69 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 5.2x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Q4 2025 results | Neutral | -4.6% | Year-end 2025 results with cash update and FDA holds/CRL disclosures. |
| Nov 06 | Q3 2025 results | Positive | -3.8% | Q3 2025 update with clear timelines for RGX-202 and RGX-121 and strong cash. |
| Aug 07 | Q2 2025 results | Positive | -4.0% | Q2 2025 progress, stronger cash, royalty deal and AbbVie milestone potential. |
| May 12 | Q1 2025 results | Positive | +2.6% | Q1 2025 swing to net income on Nippon Shinyaku deal and pipeline advances. |
| Mar 13 | FY 2024 results | Positive | +2.6% | FY 2024 update with major Nippon Shinyaku partnership and BLA submission. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have typically produced modest downside for RGNX, with an average move of -1.43% and several negative reactions despite constructive pipeline updates.
Across the last five earnings releases from Mar 13, 2025 through Mar 5, 2026, REGENXBIO repeatedly highlighted progress in RGX-202, RGX-121 and sura-vec while maintaining cash runway into early 2027. Financials showed fluctuating revenues and persistent net losses, offset by partnerships and royalty agreements. Market reactions were often negative even when summaries emphasized strategic wins and strengthened balance sheet, suggesting investors scrutinized risk, regulatory setbacks, and cash burn alongside clinical milestones.
Key Terms
phase iii medical
microdystrophin medical
surrogate endpoint medical
diabetic retinopathy medical
subretinal medical
suprachoroidal medical
clinical hold regulatory
accelerated approval regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE® study of RGX-202
- Primary endpoint achieved with high statistical significance
- Statistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA, n=9), supporting validity of surrogate endpoint
- Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track toward key catalysts
- Sites activated in pivotal Phase IIb/III study for diabetic retinopathy; first patient dosed expected Q2 2026
- Subretinal wet AMD topline pivotal data expected in Q4 2026
- Clinical hold lifted for RGX-121
- Webcast today at 8:00 a.m. ET to discuss RGX-202 topline pivotal data and Q1 2026 earnings
"REGENXBIO enters a transformative year with positive momentum, reaching significant late-stage milestones to support our potential first- and best-in-class gene therapies," said Curran Simpson, President and Chief Executive Officer, REGENXBIO. "On our mission to bring meaningful new therapies to rare disease communities facing limited options, we remain focused on advancing RGX-202 for Duchenne toward potential BLA submission and are excited to share topline pivotal data in our webcast today; we also continue engaging with the FDA regarding a potential path forward for RGX-121 for Hunter syndrome. In chronic retinal diseases, we are executing against our multi-indication strategy and preparing for the Phase 3 wet AMD readout with partner AbbVie. Additionally, we continue harnessing internal manufacturing capabilities to support anticipated commercial needs. We remain well-positioned to capitalize on several near-term, high-value opportunities and bring these highly differentiated treatments to patients."
PROGRAM HIGHLIGHTS AND MILESTONES
Neuromuscular Disease: RGX-202 is a potential best-in-class gene therapy for Duchenne muscular dystrophy (Duchenne). RGX-202 is designed to address the underlying cause of Duchenne by enabling targeted expression of a novel microdystrophin that is closest to naturally occurring dystrophin. It is the only microdystrophin that includes the C-Terminal domain, which has been shown to protect and preserve muscle function. The differentiated therapeutic approach behind RGX-202 includes a novel construct, a proactive immune suppression regimen, and a suspension-based manufacturing process that delivers industry-leading product purity levels. RGX-202 is designed for improved muscle function, durability and positive safety outcomes and is being evaluated in the Phase I/II/III AFFINITY DUCHENNE® trial in ambulatory patients aged 1+.
- REGENXBIO today announced positive topline results from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202, including primary endpoint (n=30 at Week 12), interim safety (n=31), and interim functional data (n=9 at 12 months):[1]
- Achieved primary endpoint with high statistical significance;
93% of patients achieved RGX-202 microdystrophin expression above10% (p<0.0001) - RGX-202 was well-tolerated, continued to demonstrate a favorable interim safety profile.
- Achieved primary endpoint with high statistical significance;
- Statistically significant correlation between RGX-202 microdystrophin expression level and functional improvement (NSAA, n=9), supporting the validity of the surrogate endpoint.
- More than 20 additional participants have been enrolled in the confirmatory trial of RGX-202 (n=30), and the Company expects to have completed dosing in all 60 patients across the pivotal and confirmatory trials by mid-year.
- REGENXBIO continues to manufacture intended commercial supply of RGX-202 at its in-house Manufacturing Innovation Center.
- Topline data supports plans for potential accelerated approval in 2027.
____________________________ |
1 30 of 31 total participants have Week 12 biopsy available for evaluation; one participant refused muscle biopsy. |
Retinal Disease: Surabgene lomparvovec (sura-vec, ABBV-RGX-314), developed in collaboration with AbbVie, is potentially the first-in-class gene therapy treatment for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).
Sura-vec for the Treatment of Wet AMD (Subretinal Delivery)
- REGENXBIO expects to share topline data with AbbVie from ATMOSPHERE® and ASCENT® pivotal trials of sura-vec using subretinal delivery in Q4 2026.
- Global regulatory submissions are expected in 2027.
Sura-vec for the Treatment of DR (Suprachoroidal Delivery)
U.S. clinical sites are active and initiating enrollment in the Phase IIb/III NAAVIGATE study. NAAVIGATE is a Phase IIb/III multicenter, randomized, masked, sham-controlled study to evaluate the safety and efficacy of sura-vec in subjects with non-proliferative DR (NPDR) without center-involved diabetic macular edema (CI-DME).- REGENXBIO will receive a
$100 million
Sura-vec for the Treatment of Wet AMD (Suprachoroidal Delivery)
- Enrollment is complete in the Phase II AAVIATE® trial.
Neurodegenerative Disease: Clemidsogene lanparvovec (RGX-121) is a potential first-in-class treatment for Mucopolysaccharidosis (MPS) Type II, also known as Hunter syndrome. RGX-111 is an investigational one-time treatment for severe MPS I, also known as Hurler syndrome. These programs are partnered with Nippon Shinyaku.
- The FDA has lifted the partial clinical hold on RGX-121.
- REGENXBIO recently filed an appeal of the 121 CRL and is continuing to engage the agency regarding a path forward for the program.
FINANCIAL RESULTS
Cash Position: Cash, cash equivalents and marketable securities were
Revenues: Revenues were
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative Expenses: General and administrative expenses were
Net Income: Net loss was
FINANCIAL GUIDANCE
REGENXBIO expects its balance in cash, cash equivalents and marketable securities of
CONFERENCE CALL
REGENXBIO will host a conference call and webcast at 8:00 a.m. ET today to discuss the RGX-202 topline data as well as first quarter 2026 updates. The live webcast can be accessed here and in the Investor section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.REGENXBIO.com.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timing or likelihood of payments from AbbVie or Nippon Shinyaku, the monetization of any priority review voucher, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the
Zolgensma® and Itvisma® are registered trademarks of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.
CONTACTS:
Dana Cormack
Corporate Communications
Dcormack@regenxbio.com
George E. MacDougall
Investor Relations
IR@regenxbio.com
REGENXBIO INC. | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
(unaudited) | ||||||||
(in thousands) | ||||||||
March 31, 2026 | December 31, 2025 | |||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 15,229 | $ | 34,466 | ||||
Marketable securities | 135,262 | 195,604 | ||||||
Accounts receivable | 10,038 | 26,379 | ||||||
Prepaid expenses | 11,543 | 11,927 | ||||||
Other current assets | 14,444 | 12,905 | ||||||
Total current assets | 186,516 | 281,281 | ||||||
Marketable securities | — | 10,785 | ||||||
Accounts receivable | 420 | 2,312 | ||||||
Property and equipment, net | 101,874 | 104,855 | ||||||
Operating lease right-of-use assets | 45,541 | 47,156 | ||||||
Restricted cash | 2,030 | 2,030 | ||||||
Other assets | 5,513 | 4,613 | ||||||
Total assets | $ | 341,894 | $ | 453,032 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 21,207 | $ | 21,358 | ||||
Accrued expenses and other current liabilities | 21,892 | 38,390 | ||||||
Deferred revenue | 5,919 | 10,452 | ||||||
Operating lease liabilities | 7,867 | 8,286 | ||||||
Royalty monetization liabilities | 14,225 | 39,609 | ||||||
Total current liabilities | 71,110 | 118,095 | ||||||
Deferred revenue | 22,776 | 18,943 | ||||||
Operating lease liabilities | 63,199 | 65,215 | ||||||
Royalty monetization liabilities | 163,105 | 147,408 | ||||||
Other liabilities | 622 | 638 | ||||||
Total liabilities | 320,812 | 350,299 | ||||||
Stockholders' equity | ||||||||
Preferred stock; no shares issued and outstanding | — | — | ||||||
Common stock; 51,617 and 50,892 shares issued | 5 | 5 | ||||||
Additional paid-in capital | 1,238,025 | 1,229,442 | ||||||
Accumulated other comprehensive loss | (870) | (687) | ||||||
Accumulated deficit | (1,216,078) | (1,126,027) | ||||||
Total stockholders' equity | 21,082 | 102,733 | ||||||
Total liabilities and stockholders' equity | $ | 341,894 | $ | 453,032 | ||||
REGENXBIO INC. | ||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) | ||||||||
(unaudited) | ||||||||
(in thousands, except per share data) | ||||||||
Three Months Ended March 31, | ||||||||
2026 | 2025 | |||||||
Revenues | ||||||||
License and royalty revenue | $ | 5,090 | $ | 87,049 | ||||
Service revenue | 1,303 | 1,963 | ||||||
Total revenues | 6,393 | 89,012 | ||||||
Operating Expenses | ||||||||
Cost of license and royalty revenues | 11,074 | 3,436 | ||||||
Research and development | 57,339 | 53,087 | ||||||
General and administrative | 21,306 | 20,347 | ||||||
Other operating expenses | 36 | 15 | ||||||
Total operating expenses | 89,755 | 76,885 | ||||||
Income (loss) from operations | (83,362) | 12,127 | ||||||
Other Income (Expense) | ||||||||
Interest income from licensing | 16 | 25 | ||||||
Investment income | 2,003 | 2,501 | ||||||
Interest expense | (8,708) | (8,570) | ||||||
Total other income (expense) | (6,689) | (6,044) | ||||||
Net income (loss) | $ | (90,051) | $ | 6,083 | ||||
Other Comprehensive Loss | ||||||||
Unrealized loss on available-for-sale securities, net | (183) | (21) | ||||||
Total other comprehensive loss | (183) | (21) | ||||||
Comprehensive income (loss) | $ | (90,234) | $ | 6,062 | ||||
Net income (loss) per share: | ||||||||
Basic | $ | (1.72) | $ | 0.12 | ||||
Diluted | $ | (1.72) | $ | 0.12 | ||||
Weighted-average common shares outstanding: | ||||||||
Basic | 52,428 | 51,362 | ||||||
Diluted | 52,428 | 51,434 | ||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-reports-first-quarter-2026-financial-results-and-operational-highlights-302771841.html
SOURCE REGENXBIO Inc.